莫努匹韦用法用量？

Monupivir is administered orally to patients over 18 years of age, 800 mg twice a day for 5 days, before or after meals. The specification of Monupivir is 200 mg per pill; 40 pills per bottle, which means 4 pills of Monupivir are taken orally each time, 8 pills per day. Monupivir is contraindicated in patients with a history of hypersensitivity to its components, and in women who are pregnant or may become pregnant.

Monupivir is an anti-COVID-19 oral drug produced by Merck, also known as molnupiravir, monapiravir, and monoravir. On December 29, 2022, the State Food and Drug Administration conducted an emergency review and approval in accordance with the relevant provisions of the "Drug Administration Law" and in accordance with the special drug approval procedures, and approved the marketing with conditions.

How much does it cost to take Monupivir for 5 days?

At present, we know that the price of Monupivir in the overseas market is about $350 per box. The specifications are 200 mg per pill; 40 pills per bottle, which is just enough for 5 days in one bottle. In the domestic market, a course of treatment costs about US$700, or approximately RMB 4,700. Patients can choose the version they want to use based on their own conditions. It can be purchased at domestic hospital pharmacies or obtained through domestic professional overseas medical service institutions. The medicine can be directly mailed to your home from overseas. It is guaranteed to be genuine and at an affordable price. For more details, patients can consult customer service personnel.

How does Monupivir treat COVID-19?

Monupivir is an oral antiviral drug that is a potent ribonucleoside analog that can inhibit the replication of a variety of RNA viruses, including SARS-CoV-2 (the causative agent of COVID-19). It is a drug used to treat mild to moderate COVID-19 infections in adults. A phase 2 DBPRC study found that in patients with mild to moderate COVID-19 infection, taking monupivir 800 mg twice daily significantly shortened clearance time (RNA negativity) compared with placebo (log-rank p value = 0.013).

Recommended related articles:

References

Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102329. doi: 10.1016/j.dsx.2021.102329. Epub 2021 Oct 30. PMID: 34742052; PMCID: PMC8556684.